AM833 (cagrilintide) showed a unique pharmacological profile across diverse measures of receptor binding, activation and regulation compared with other selective and nonselective calcitonin and amylin receptor agonists.
In plain wordsIn lab tests, AM833 (cagrilintide) acted on receptors differently from other amylin and calcitonin drugs.
- Peptide
- Cagrilintide
- Outcome
- Not applicableReceptor binding, activation and regulation profile of AM833
- Study
n: not reported in source
- Comparator
- AMYR-selective and nonselective analogs, pramlintide, salmon CT
- Outcome group
- Receptor activity and mechanism · Pharmacology
- Studied dose
- Dose not stated
Source sentences
Our results demonstrate that AM833 has a unique pharmacological profile across diverse measures of receptor binding, activation, and regulation.
1 context sentence(design, population, supporting numbers)
In the current study, we have investigated the pharmacology of AM833 across 25 endpoints and compared this peptide with AMYR selective and nonselective lipidated analogs (AM1213 and AM1784), and the clinically used peptide agonists pramlintide (AMYR selective) and salmon CT (nonselective).